Eton Pharma up on FDA nod for Biorphen

Thinly traded nano cap Eton Pharmaceuticals (NASDAQ:ETON) is up 20% premarket on increased volume in reaction to the FDA’s approval of Biorphen, a ready-to-use formulation of phenylephrine for the treatment of hypotension (low blood pressure) resulting primarily from anesthesia-associated vasodilation (widening of blood vessels from relaxation of smooth muscle cells within vessel walls).

Previously, phenylephrine injection was only available in a highly concentrated formulation requiring dilution prior to use or in ready-to-use formulations from compounding pharmacies.

https://seekingalpha.com/news/3507682-eton-pharma-20-percent-premarket-fda-nod-biorphen